Last reviewed · How we verify
NCT03604120: PREOPTI-DAM
Preoxygenation for Difficult Airway Management
NA trial testing Preoxygenation with high flow therapy by nasal cannula in Intubation;Difficult in 186 participants. Completed in 8 March 2021.
8 March 2021
Quick facts
| Lead sponsor | Nantes University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 186 |
| Start date | 19 September 2018 |
| Primary completion | 8 March 2021 |
| Estimated completion | 8 March 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- Preoxygenation with high flow therapy by nasal cannula
- Preoxygenation by standard Facial mask
Conditions studied
- Intubation;Difficult — all drugs for Intubation;Difficult →
Sponsor
Nantes University Hospital
Who can join
18 and older, any sex, with Intubation;Difficult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tracheal intubation in operating room for patients at risk of difficult intubation remains a critical event. The aim of this study is to determine whether Nasal High Flow Therapy by nasal cannula Optiflow® administered before and during intubation is more efficient than the standard care for pre-oxygenation and oxygenation during anticipated difficult intubation
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Preoxygenation in difficult airway management: high-flow oxygenation by nasal cannula versus face mask (the PREOPTIDAM study). Protocol for a single-centre randomised study.
Vourc'h M, Huard D, Feuillet F, Baud G, et al · · 2019 · cited 9× · PMID 31028041 · DOI 10.1136/bmjopen-2018-025909 -
High-flow oxygen therapy versus facemask preoxygenation in anticipated difficult airway management (PREOPTI-DAM): an open-label, single-centre, randomised controlled phase 3 trial.
Vourc'h M, Huard D, Le Penndu M, Deransy R, et al · · 2023 · cited 6× · PMID 37251624 · DOI 10.1016/j.eclinm.2023.101998
Verify or expand the search:
- PubMed search for NCT03604120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Nantes University Hospital trials
Trials by the same sponsor.
- NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
- NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
- NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03604120 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
- Last refreshed: 11 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03604120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing